Ventana President Mara Aspinall: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
In the midst of a busy January – in which Ventana has signed four publicly disclosed deals to develop companion diagnostics with pharma partners – Ventana President Mara Aspinall talked with “The Pink Sheet” DAILY about pharma’s evolving attitude on personalized medicine, sharing value for joint projects and how Ventana is positioning itself to be the partner of choice for pharma.
You may also be interested in...
Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.
Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.
Laboratory-developed tests are not explicitly mentioned in FDA’s 12-page draft guidance on companion diagnostics issued this summer, but the issue attracted significant attention in written comments in response to the document.